Information Provided By:
Fly News Breaks for August 5, 2015
ECYT
Aug 5, 2015 | 07:08 EDT
Cantor reports that the maximum tolerated dose of Endocyte's EC1456 has been reached sooner than expected. As a result, the firm believes that the drug has greater safety and can support higher doses than the previous generation of the drug, EC1169. The firm keeps a $21 price target and Buy rating on the shares.
News For ECYT From the Last 2 Days
There are no results for your query ECYT